Switzerland-based company Fresenius Kabi announced that its pegfilgrastim biosimilar received marketing authorization in Europe and that it has obtained a majority stake in biosimilar manufacturer mAbxience and acquired its subsidiary.
Fresenius Kabi accomplished 3 biosimilar targets recently, with the announcement of its pegfilgrastim biosimilar receiving the green light from the European Commission, its purchase of a majority stake in biosimilar manufacturer mAbxience, and its acquisition of Ivenix.
European Approval of Pegfilgrastim Biosimilar
The European Commission authorized Fresenius Kabi’s Stimufend, a biosimilar referencing Neulasta, for marketing across the European Union, making it the company’s first European approval for an oncology biosimilar and second European approval overall. Stimufend was approved for all of the same indications as the reference product.
Pegfilgrstim products are used in patients with nonmyeloid cancer who are undergoing myelosuppressive chemotherapy and are at risk of febrile neutropenia, a common chemotherapy-related complication characterized by a low level of certain white blood cells, which can be life-threatening.
“With the approval of this new biosimilar product in Europe, we are leveraging our heritage in oncology and expanding our oncology portfolio to better support the treatment experience and clinical outcomes for patients with cancer. We are proud to be ‘caring for life’ and to continue to deliver high-quality and affordable therapies for cancer and autoimmune diseases, while easing the burden on local healthcare systems,” said Michael Schönhofen, PhD, chief operating officer and board member at Fresenius Kabi, in a company statement.
The company said that it is expected to launch a prefilled syringe of the biosimilar in several European markets over the coming months. Fresenius Kabi has also filed for regulatory approval for Stimufend in the United States, where is currently under review by the FDA.
Two Big Acquisitions
Additionally, the Switzerland-based company announced that it bought a majority stake (55%) in mAbxience and fully acquired Ivenix, a specialized infusion therapy company.
Fresenius Kabi will give mAbxience €495 million in upfront and milestone payments. The purchase of Ivenix will cost Fresenius Kabi $240 million in similar payments that will be strictly linked to the achievement of commercial and operating targets.
The majority stake will provide Fesenius Kabi a strong partnership with growth potential in biosimilar markets. mAbxience currently has 2 commercialized biosimilars, a rituximab product and a bevacizumab product.
Through Fresenius Kabi’s in-house biosimilars programs and its investment in mAbxience, Fresenius Kabi said that it expects to capture an overproportionate share of the underlying rapid growth in the biopharmaceutical market. The deal is expected to close by mid-year 2022.
Ivenix was a privately held company based in North Andover, Massachusetts in the United States. The company has developed the an advanced infusion system, which features a large volume pump with administration sets, infusion management software tools, applications and analytics access to inform care and advance infusion efficiency. The Ivenix Infusion System was approved by the FDA and launched in late 2021. The transaction is expected to close by the middle of 2022.
“Through these acquisitions we are further strengthening and leveraging Fresenius Kabi's position, as both perfectly complement the company's growth businesses in biopharmaceuticals and medical technology….In this way, we are creating even better conditions for providing ever better medicine to ever more people. At the same time, we create meaningful value for our shareholders,” said Stephan Surm, CEO of Fresenius, Fresenius Kabi’s parent company, in another company statement.
Michael Sen, CEO of Fresenius Kabi, continued, “With the acquisition of Ivenix, we add the next generation infusion therapy platform; we complement and strengthen our existing infusion therapy offering and we create a superior portfolio for the US market. With mAbxience, we are making a step-change in our biopharmaceuticals profile. This is a highly complementary transaction in terms of biologics pipeline, manufacturing capabilities and the business model. mAbxience is two businesses in one company. mAbxience and Ivenix as portfolio advancements are good for patients, good for healthcare providers and our company.”
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Development Roundup: October 2024
October 31st 2024In October, the GRx+Biosims conference included discussions on data transparency, artificial intelligence, and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.